Shots:

• The P-II DESTINY-Breast01 study involves assessing of trastuzumab deruxtecan in 184 patients with HER2+ unresectable/ mBC prior treated with trastuzumab emtansine across 100 sites globally
• The P-II DESTINY- Breast01 study results: ORR (60.9%); DCR (97.3%); mDOR (14.8mos.); mPFS (16.4 mos.); estimated OS @12mos. (86%); safety & tolerability profile is consistent with P-I study
• Trastuzumab deruxtecan (DS-8201 in the US) is a HER2-targeting ADC- jointly develop & commercialize by AstraZeneca and Daiichi Sankyo globally (Ex-Japan) where Daiichi Sankyo retains exclusive rights for the product. In Oct’2019- the FDA has accepted its BLA and granted PR designation to the therapy

Click here to­ read full press release/ article 

 Ref: AstraZeneca | Image: Delaware Business Times